Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 5/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.51 |
| ▸ | HRH1 | P35367 | 3/20 | 0.44 |
| ▸ | USP7 | Q93009 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.42 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL17009566 | 0.98 | HTR1A (0.50) | HTR1ASLC6A2SLC6A3HRH1USP7 | |
| SCHEMBL15087982 | 0.83 | SLC6A4 (0.51) | HTR1ASLC6A2SLC6A3SLC6A4 | |
| SCHEMBL941030 | 0.83 | SLC6A2 (0.58) | HTR1ASLC6A2SLC6A3HRH1SLC6A4 | |
| Hydrochloric Acid SCHEMBL2778482 | 0.82 | SLC6A2 (0.56) | HTR1ASLC6A2SLC6A3HRH1SLC6A4 | |
| SCHEMBL30422771 | 0.81 | SLC6A2 (0.52) | HTR1ASLC6A2SLC6A3HRH1SLC6A4 | |
| SCHEMBL5367403 | 0.81 | HTR2C (0.54) | HTR1ASLC6A2SLC6A3SLC6A4HTR2C | |
| SCHEMBL2252843 | 0.81 | HTR1A (0.51) | HTR1ASLC6A2SLC6A3HRH1SLC6A4 | |
| SCHEMBL13419259 | 0.81 | SLC6A2 (0.52) | HTR1ASLC6A2SLC6A3HRH1SLC6A4 | |
| SCHEMBL28086900 | 0.81 | HTR1A (0.51) | HTR1ASLC6A2SLC6A3HRH1SLC6A4 | |
| SCHEMBL31071547 | 0.78 | HTR2C (0.49) | HTR1ASLC6A2SLC6A3HRH1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3105230-B1 | PYRIDOPYRAZINES MODULATORS OF GPR6 | TAKEDA PHARMACEUTICALS CO (JP) | 2021-04-07 | — | — | EP | disclosed |
| US-10597392-B2 | Tetrahydropyridopyrazines as modulators of GPR6 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-03-24 | — | — | US | disclosed |
| US-20190263801-A1 | TETRAHYDROPYRIDOPYRAZINES MODULATORS OF GPR6 | ENVOY THERAPEUTICS, INC. | 2019-08-29 | — | — | US | disclosed |
| US-10179783-B2 | Tetrahydropyridopyrazines as modulators of GPR6 | Taketa Pharmaceutical Company Limited (JP) | 2019-01-15 | — | — | US | disclosed |
| US-9770452-B2 | Quinoxaline derivatives as GPR6 modulators | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-26 | — | — | US | disclosed |
| US-20170174677-A1 | TETRAHYDROPYRIDOPYRAZINES MODULATORS OF GPR6 | ENVOY THERAPEUTICS, INC. | 2017-06-22 | — | — | US | disclosed |
| US-20170035775-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | ENVOY THERAPEUTICS, INC. | 2017-02-09 | — | — | US | disclosed |
| EP-3105230-A1 | PYRIDOPYRAZINES MODULATORS OF GPR6 | Takeda Pharmaceutical Company Limited (JP) | 2016-12-21 | — | — | EP | disclosed |
| US-9487526-B2 | Quinoxaline derivatives as GPR6 modulators | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-08 | — | — | US | disclosed |
| EP-2882722-B1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | TAKEDA PHARMACEUTICAL (JP) | 2016-07-27 | — | — | EP | disclosed |
| WO-2015123505-A1 | PYRIDOPYRAZINES MODULATORS OF GPR6 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-20 | — | — | WO | disclosed |
| US-20150232469-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | ENVOY THERAPEUTICS, INC. | 2015-08-20 | — | — | US | disclosed |
| EP-2882722-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | Envoy Therapeutics Inc. (US) | 2015-06-17 | — | — | EP | disclosed |
| WO-2014028479-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | ENVOY THERAPEUTICS, INC. (US) | 2014-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232469-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | GPR6, GRM6, GPR65 | HTR1A 118/4885SLC6A2 178/4885SLC6A3 44/4885 |
| US-10597392-B2 | Tetrahydropyridopyrazines as modulators of GPR6 | GPR6, GPR65, GPR52 | HTR1A 179/4885SLC6A2 618/4885SLC6A3 666/4885 |
| US-10179783-B2 | Tetrahydropyridopyrazines as modulators of GPR6 | GPR6, GPR65, GPR52 | HTR1A 179/4885SLC6A2 618/4885SLC6A3 666/4885 |
| US-20190263801-A1 | TETRAHYDROPYRIDOPYRAZINES MODULATORS OF GPR6 | GPR6, GPR52, GPR65 | HTR1A 182/4885SLC6A2 667/4885SLC6A3 678/4885 |
| US-20170035775-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | GPR6, GRM6, GPR65 | HTR1A 118/4885SLC6A2 178/4885SLC6A3 44/4885 |
| US-20170174677-A1 | TETRAHYDROPYRIDOPYRAZINES MODULATORS OF GPR6 | GPR6, GPR52, GPR65 | HTR1A 182/4885SLC6A2 667/4885SLC6A3 678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.